Effect of Aerobic Interval Training on Atrial Fibrillation Burden

Launched by NAVY GENERAL HOSPITAL, BEIJING · Jun 30, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how aerobic interval training, which includes both high-intensity and moderate-intensity exercise, affects patients with non-permanent atrial fibrillation, a common heart condition that can lead to serious health issues like stroke and heart failure. The study will last for 12 weeks and aims to see if this type of exercise can reduce the frequency of atrial fibrillation episodes and improve overall heart health, fitness, and quality of life for participants. Researchers will also monitor any exercise-related side effects during the trial.

To participate in this study, individuals must be between 18 and 74 years old and have a diagnosis of non-permanent atrial fibrillation. They should have a resting heart rate of 110 beats per minute or less and should not have engaged in a formal exercise program in the last six months. Participants will need to provide informed consent and follow up as required. However, certain health conditions, such as recent heart surgery or severe heart disease, may exclude someone from joining the study. If eligible, participants can expect to engage in guided exercise sessions while being closely monitored for their safety and health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age range: 18-74 years;
• • 2. Patients with non-permanent atrial fibrillation;
• • 3. Resting heart rate ≤110 beats/min;
• • 4. No history of receiving a formal exercise prescription within the past six months;
• • 5. Willing to participate in this study, provide written informed consent, and agree to comply with follow-up procedures.
• Exclusion Criteria:
• • 1. History of myocardial infarction, endocarditis/myocarditis/pericarditis, stroke (ischemic/hemorrhagic), pulmonary embolism, lower extremity venous thrombosis, or cardiac surgery within the past 6 months;
• • 2. Moderate to severe pulmonary arterial hypertension, moderate to severe valvular heart disease, hypertrophic cardiomyopathy, aortic stenosis/dilation/dissection/intramural hematoma, congenital heart disease;
• • 3. Heart failure (NYHA class III-IV) or acute exacerbation of heart failure within the past 3 months;
• • 4. Unstable angina or severe coronary artery disease without revascularization;
• • 5. Concurrent severe arrhythmias
• • frequent multifocal premature ventricular contractions
• • ventricular tachycardia, ventricular fibrillation
• • high-degree or complete atrioventricular block
• • ventricular asystole lasting more than 5 seconds
• • 6. Uncontrolled hypertension or hypotension;
• • 7. Severe renal or hepatic dysfunction
• • Stage 5 chronic kidney disease, defined as glomerular filtration rate \<15 ml/(min•1.73 m2) or requiring dialysis;
• • Patient with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than or equal to 5 times the upper limit of normal as defined by the center during screening;
• • 8. Hypoxemia or severe lung disease;
• • 9. Lower extremity arterial stenosis or musculoskeletal disease preventing exercise training;
• • 10. Intracardiac thrombus;
• • 11. Pregnancy;
• • 12. Cognitive impairment preventing study cooperation;
• • 13. Severe anemia, infection, electrolyte disturbances, hyperthyroidism;
• • 14. Planned atrial fibrillation ablation during the study period;
• • 15. Post-implantation of pacemaker or ICD;
• • 16. Inability to use smart devices;
• • 17. Concurrent cancer or autoimmune or systemic inflammatory disease;
• • 18. Regular moderate-to-high intensity exercise habits (≥2 sessions of high-intensity endurance training per week or ≥3 sessions of moderate-intensity endurance training